Center for Neuro-Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Surg Pathol Clin. 2020 Jun;13(2):209-215. doi: 10.1016/j.path.2020.02.003. Epub 2020 Apr 7.
Recent discoveries elucidating the genetic underpinnings of glial neoplasms have revealed myriad recurrent alterations that have clinical value by improving accuracy of diagnosis and prognosis. Furthermore, this wealth of genomic information provides the basis for targeted therapies and the subsequent design of biomarker-based clinical trials. This review summarizes the current landscape of clinically relevant molecular alterations in gliomas and describes the role of routine molecular testing in context of treatment planning for standards of care and clinical trials.
最近的研究揭示了神经胶质肿瘤的遗传基础，发现了无数具有临床价值的复发性改变，提高了诊断和预后的准确性。此外，这些丰富的基因组信息为靶向治疗和随后基于生物标志物的临床试验的设计提供了基础。本综述总结了目前胶质瘤中具有临床意义的分子改变，并描述了常规分子检测在治疗计划中的作用，包括护理标准和临床试验。
